Ann: Trading Halt, page-17

Let's trust in AF and management to make strategic acquisitions at the appropriate time to accelerate growth for the long term.

Imbio is growing very quickly and is cash-flow positive and probably wouldn't go for this price next year or the year after when its revenue is much higher (and potential profitability) and the acquisition would probably significantly enhance 4DMedical's products and company's profile.

Imbio would also have a large customer list that we can leverage to upsell 4DMedical's suite / pipeline of products.

If you look at Imbio's product suite, you will see a large array of lung analysis products (and FDA cleared where applicable). And a heart product (coronary artery analysis) too!

At first sight and when you see capital raise it might sound curious as to "why", but when you look further (and I'm sure the company will fully explain this), you will find that this is money very well spent for A$30m (and potentially cheap on a LT basis). If you think about the money we would need to spend to conduct R&D to produce or reproduce all these products and then money to achieve FDA approvals for the products and then the marketing/commercialisation costs to get the company to $9m revenue per year and growing at 112 per cent, you'd see that this is great value for money!!

We are also taking out potential similar competition. Remember PME acquired Visage and turned that into a real money spinner and to the company of its multi billion dollar market cap. It also makes sense why we met Minnesota governor and trade delegation in Melbourne recently.

All in all, after reflecting about this with high level research, and keen to see the company's presentation on the rationale, I think investors should see this as a very good acquisition, and potentially material/game-changing for the company's sustainable future.